Bolt Biotherapeutics Inc

NASDAQ:BOLT 3:58:38 PM EDT

1.16

-0.04 (-3.35%)

6:55:09 PM EDT: $1.20 +0.04 (+3.45%)

Market Cap (Intraday)	44.23M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$2.08 Million
Adjusted EPS	-$0.50

See more estimates

10-Day MA	$1.17
50-Day MA	$1.21
200-Day MA	$1.12

See more pivots

Bolt Biotherapeutics Inc Stock, NASDAQ:BOLT

900 Chesapeake Drive, Redwood City, California 94063

United States of America

Phone: +1.650.665.9295

Number of Employees: 100

http://www.boltbio.com

Description

Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer. Its pipeline includes BDC-1001, a HER2-targeting Boltbody Immune-Stimulating Antibody Conjugate (ISAC), BDC-3042, a myeloid-modulating antibody, and multiple Boltbody ISAC collaboration programs. The company was founded by Edgar G. Engleman on January 22, 2015 and is headquartered in Redwood City, CA.